Search
Tea tree oil
go.drugbank.com/drugs/DB11218ApprovedNutraceuticalTea tree oil is an essential oil derived mainly from the Australian native plant _Melaleuca alternifolia_ via steam distillation of the of the leaves and terminal branches [A32439]. … It has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438].
Synonyms: Snow-in-summer leaf oilPyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
Products: PYRAFAT 500MG, PYRAZINAMID 500MG JENAPHButamben
go.drugbank.com/drugs/DB11148ApprovedWithdrawnButamben is a local anesthetic in the form of n-butyl-p-aminobenzoate. … [A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics.
Diclofenamide
go.drugbank.com/drugs/DB01144ApprovedA carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Mecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalIn 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075]. … Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].
Doxacurium
go.drugbank.com/drugs/DB01135ApprovedWithdrawnDoxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Agalsidase beta
go.drugbank.com/drugs/DB00103ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … [A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383]
Bezlotoxumab
go.drugbank.com/drugs/DB13140Approved[A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191] … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.
Aprotinin
go.drugbank.com/drugs/DB06692ApprovedInvestigationalWithdrawnThe goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. … Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death.